Clene Inc. (CLNN) stock
Close on Nov 12, 2026Market cap $51.39MP/E –Yield –
Clene Inc. grew revenue 11.2% to $238.00K over the twelve months to Sep 30, 2026. Free cash flow was -$18.59M. At the latest close the market valued the company at $51.39M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $51.39M
- P/E ratio
- –
- Price to sales
- 215.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $238.00K
- Net income
- -$26.83M
- EPS, diluted
- -$2.58
- Free cash flow
- -$18.59M
- Book value per share
- -$1.01
- Diluted shares
- 15M
Trading
- Next earnings
- Mar 11, 2027 (estimated, before the open)
- Previous close
- $4.20
- Open
- $4.16
- Day's range
- $3.92 – $4.25
- Volume
- 109,073
- Average volume (20 days)
- 98,640
- Beta (5 years)
- 0.80
- 52-week range
- $3.02 – $10.84
- RSI (14 days)
- 56.2
- Volatility (1 year)
- 94.9%
- Relative volume
- 2.16×
- WACC
- 8.9%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLNN | S&P 500 | Difference | CLNN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.7% | -2.7% | +11.4 pts | ||
| 3 months | -1.7% | -1.7% | +0.0 pts | ||
| Year to date | -31.9% | +11.9% | −43.8 pts | ||
| 1 year | -57.5% | +12.0% | −69.5 pts | ||
| 3 years | -55.6% | +78.2% | −133.7 pts | -23.7% | +21.2% |
| 5 years | -96.3% | +73.2% | −169.6 pts | -48.4% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Clene filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Update
- Update
About Clene
Pharmaceutical Preparations
This clinical-stage pharmaceutical company develops clean-surfaced nanotechnology therapeutics designed to treat neurodegenerative diseases and central nervous system disorders, including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease. Its proprietary platform synthesizes stable, highly catalytic nanocrystals from transition elements without toxic organic residues. The company's lead drug asset is an orally administered gold nanocrystal suspension engineered to restore cellular energy metabolism, increase intracellular adenosine triphosphate production, and reduce oxidative stress and toxic protein aggregates. Additional pipeline candidates in early development include ionic solutions for infectious diseases and wound healing. It also markets mineral dietary supplements, either directly through a subsidiary or via licensing partnerships with supplement distributors.
Company profile, executives and historyClene stock: common questions
What is Clene's stock price?
CLNN closed at $4.00 on Nov 12, 2026, down 4.65% on the day. Over the past 52 weeks it traded between $3.02 and $10.84.
What is Clene's market cap?
Clene was worth $51.39M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CLNN's P/E ratio?
Clene lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.58), so it has no meaningful P/E ratio.
How much revenue does Clene make?
Clene reported revenue of $238.00K for the twelve months to Sep 30, 2026, up 11.2% from a year earlier.
Does Clene pay a dividend?
No. Clene has not paid a cash dividend over the last twelve months.
When does Clene report earnings next?
Clene is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CLNN stock performed over the past year?
Including dividends, CLNN returned -57.5% over the past year, against +12.0% for the S&P 500.
How many CLNN shares are sold short?
0M shares were sold short at the latest FINRA report, 5.99% of the float, or 5.1 days of average trading volume.
Who are Clene's competitors?
Companies most similar to Clene by business, industry and size include SER, ABVC, LEXX, IXHL, VCNX.
See a number that looks wrong?